QGEN
QIAGEN NV
NYSE · Healthcare · Medical - Diagnostics & Research · NL
$46.55
+0.91%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$46.18
From 52W high−16.37%
Volume2.16M
Market cap$9.61B
P/E (TTM)23.9x
P/S (TTM)4.6x
Div yield5.93%
Key dataOct 19, 2026
Open
$46.18
From 52W high
−16.37%
Volume
2.16M
Market cap
$9.61B
ValuationView details →
P/E (Fwd)
18.4x
EV/EBITDA
14.9x
P/E (TTM)
23.9x
RSI (14)
60.8
MomentumView details →
1D Return
+0.91%
YTD Return
−2.06%
SummaryUpdated Jun 1, 2026
QIAGEN N.V. (NASDAQ:QGEN) is a Netherlands-based multinational biotechnology company founded in 1986 that specializes in molecular diagnostics and life sciences research technologies. Originally established as a spin-off from the University of Düsseldorf, QIAGEN went public in 1996 and has grown through both organic expansion and strategic acquisitions to become a leading provider of sample preparation and molecular testing solutions. The company serves customers across molecular diagnostics, academic research, pharmaceutical development, and applied testing markets worldwide, with operations spanning over 35 countries and headquarters in Venlo, the Netherlands.
Similar companies
Latest newsMore news →
QIAGEN announced new AI capabilities for research and drug discovery, including IPA Investigator and the QIAGEN Discovery Platform.13d agoQiagen is reportedly in advanced talks with a strategic buyer regarding a potential acquisition.17d agoQiagen N.V. introduced a curated knowledge-graph foundation designed to ground AI agents used in drug discovery for biopharma companies.21d ago